Abstract
Objective: We investigated the association between overactive bladder (OAB) and urinary metabolites in men. Methods: This prospective observational study included 42 men aged 65–80 years. The 3-day frequency volume chart (FVC), International Prostate Symptom Score (IPSS), and quality of life score were adapted to assess the micturition behavior. Participants with IPSS urgency score ≥2 were included in the OAB group, and those with IPSS urgency score <2 were included in the control group. We performed a comprehensive metabolomic analysis using urine samples. Metabolites were compared between the groups using an unpaired t test and Fisher’s exact test in a nonadjusted analysis. Multivariable logistic regression analysis was performed to investigate the association between OAB and the metabolites. Results: Overall, 23 men were included in the OAB group and 19 in the control group. There were no differences in the background factors except age between the groups. FVC analysis demonstrated that nocturnal urine volume, 24-h micturition frequency, and nocturnal micturition frequency were significantly higher, and the maximum voided volume was significantly lower in the OAB group than in the controls. Metabolomic analysis revealed 14 metabolites that were differentially expressed between the groups. Multivariate analysis indicated that an increase in the levels of 5-iso prostaglandin F2α-VI (5-iPF2a-VI) and 5-methoxyindoleacetic acid was associated with OAB. Conclusion: Abnormal urinary metabolites, including metabolites in the tryptophan (5-methoxyindoleacetic acid, 3-indoleacetonitrile, and 3-hydroxyanthranilic acid) and arachidonic acid (5-iPF2a-VI) pathways, play a role in the pathogenesis of OAB in older men.
References
1.
Abrams
P
, Cardozo
L
, Fall
M
, Griffiths
D
, Rosier
P
, Ulmsten
U
, The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society
. Neurourol Urodyn
. 2002
;21
(2
):167
–78
. .2.
Stewart
WF
, Van Rooyen
JB
, Cundiff
GW
, Abrams
P
, Herzog
AR
, Corey
R
, Prevalence and burden of overactive bladder in the United States
. World J Urol
. 2003 May
;20
(6
):327
–36
. .3.
Irwin
DE
, Milsom
I
, Hunskaar
S
, Reilly
K
, Kopp
Z
, Herschorn
S
, Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study
. Eur Urol
. 2006 Dec
;50
(6
):1306
–5
; discussion 14–5. .4.
Coyne
KS
, Kvasz
M
, Ireland
AM
, Milsom
I
, Kopp
ZS
, Chapple
CR
. Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States
. Eur Urol
. 2012 Jan
;61
(1
):88
–95
. .5.
Michel
MC
. Where will the next generation of medical treatments for overactive bladder syndrome come from?
Int J Urol
. 2020 Apr
;27
(4
):289
–94
. .6.
Benner
JS
, Nichol
MB
, Rovner
ES
, Jumadilova
Z
, Alvir
J
, Hussein
M
, Patient-reported reasons for discontinuing overactive bladder medication
. BJU Int
. 2010 May
;105
(9
):1276
–82
. .7.
Andersson
KE
. Drugs for the overactive bladder: are there differences in persistence and compliance?
Transl Androl Urol
. 2017 Jun
;6
(3
):597
–601
. .8.
Mitsui
T
, Kira
S
, Ihara
T
, Sawada
N
, Nakagomi
H
, Miyamoto
T
, Metabolomics approach to male lower urinary tract symptoms: identification of possible biomarkers and potential targets for new treatments
. J Urol
. 2018 May
;199
(5
):1312
–8
. .9.
Shimura
H
, Mitsui
T
, Kira
S
, Ihara
T
, Sawada
N
, Nakagomi
H
, Metabolomic analysis of overactive bladder in male patients: identification of potential metabolite biomarkers
. Urology
. 2018 Aug
;118
:158
–63
. .10.
Hood
B
, Andersson
KE
. Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder
. Int J Urol
. 2013 Jan
;20
(1
):21
–7
. .11.
Fry
CH
, Chakrabarty
B
, Hashitani
H
, Andersson
KE
, McCloskey
K
, Jabr
RI
, New targets for overactive bladder-ICI-RS 2109
. Neurourol Urodyn
. 2020 Jun
;39 Suppl 3
(Suppl 3
):S113
–21
.12.
Chen
Z
, Kim
J
. Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases
. BMC Urol
. 2016 Mar 22
;16
:11
. .13.
Kira
S
, Mitsui
T
, Miyamoto
T
, Ihara
T
, Nakagomi
H
, Hashimoto
Y
, Urinary metabolites identified using metabolomic analysis as potential biomarkers of nocturia in elderly men
. World J Urol
. 2020 Oct
;38
(10
):2563
–9
.14.
Dentchev
T
, Yao
Y
, Pratico
D
, Dunaief
J
. Isoprostane F2alpha-VI, a new marker of oxidative stress, increases following light damage to the mouse retina
. Mol Vis
. 2007 Feb 7
;13
:190
–5
.15.
Andersson
KE
, Boedtkjer
DB
, Forman
A
. The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction
. Ther Adv Urol
. 2017 Jan
;9
(1
):11
–27
. .16.
Mossa
AH
, Shamout
S
, Cammisotto
P
, Campeau
L
. Urinary metabolomics predict the severity of overactive bladder syndrome in an aging female population
. Int Urogynecol J
. 2020 May
;31
(5
):1023
–31
. .17.
Azadzoi
KM
, Yalla
SV
, Siroky
MB
. Oxidative stress and neurodegeneration in the ischemic overactive bladder
. J Urol
. 2007 Aug
;178
(2
):710
–5
. .18.
Nomiya
M
, Sagawa
K
, Yazaki
J
, Takahashi
N
, Kushida
N
, Haga
N
, Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis-induced chronic bladder ischemia
. Neurourol Urodyn
. 2012 Jan
;31
(1
):185
–9
. .19.
Matsumoto-Miyai
K
, Yoshizumi
M
, Kawatani
M
. Regulatory effects of 5-hydroxytryptamine receptors on voiding function
. Adv Ther
. 2015 Oct
;32 Suppl 1
(Suppl 1
):3
–15
. .20.
Moro
C
, Edwards
L
, Chess-Williams
R
. 5-HT(2A) receptor enhancement of contractile activity of the porcine urothelium and lamina propria
. Int J Urol
. 2016 Nov
;23
(11
):946
–51
.21.
Konthapakdee
N
, Grundy
L
, O'Donnell
T
, Garcia-Caraballo
S
, Brierley
SM
, Grundy
D
, Serotonin exerts a direct modulatory role on bladder afferent firing in mice
. J Physiol
. 2019 Nov
;597
(21
):5247
–64
. .22.
Audhya
T
, Adams
JB
, Johansen
L
. Correlation of serotonin levels in CSF, platelets, plasma, and urine
. Biochim Biophys Acta
. 2012 Oct
;1820
(10
):1496
–501
. .23.
Haghsheno
MA
, Mellström
D
, Peeker
R
, Hammarsten
J
, Lorentzon
M
, Sundh
V
, Lower urinary tract symptoms are associated with low levels of serum serotonin, high levels of adiponectin and fasting glucose, and benign prostatic enlargement
. Scand J Urol
. 2015 Apr
;49
(2
):155
–61
. .24.
Okamoto
T
, Hatakeyama
S
, Imai
A
, Yamamoto
H
, Yoneyama
T
, Mori
K
, The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan
. World J Urol
. 2021 Jan
;39
(1
):169
–75
.25.
Wang
Q
, Liu
D
, Song
P
, Zou
MH
. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation
. Front Biosci
. 2015 Jun 1
;20
:1116
–43
. .26.
Lund
A
, Nordrehaug
JE
, Slettom
G
, Solvang
SH
, Pedersen
EK
, Midttun
Ø
, Plasma kynurenines and prognosis in patients with heart failure
. PLoS One
. 2020
;15
(1
):e0227365
. .27.
Pedersen
ER
, Svingen
GF
, Schartum-Hansen
H
, Ueland
PM
, Ebbing
M
, Nordrehaug
JE
, Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography
. Eur Heart J
. 2013 Sep
;34
(34
):2689
–96
. .28.
Cussotto
S
, Delgado
I
, Anesi
A
, Dexpert
S
, Aubert
A
, Beau
C
, Tryptophan metabolic pathways are altered in obesity and are associated with systemic inflammation
. Front Immunol
. 2020
;11
:557
. .29.
He
Q
, Wang
Z
, Liu
G
, Daneshgari
F
, MacLennan
GT
, Gupta
S
. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links
. Prostate Cancer Prostatic Dis
. 2016 Mar
;19
(1
):7
–13
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
